Rubicon Research, a specialty pharmaceutical company, has acquired Impopharma Canada with operations in Ontario, Canada as part of its ongoing effort to establish a global development network.
Impopharma offers comprehensive drug product formulation and process development, as well as wide-ranging analytical testing services to the pharmaceutical industry, specialising in nasal and pulmonary drug products.
Over the next several months, Rubicon plans to establish development plans for a mix of both internal and external development projects.
“I welcome the Impopharma team to the Rubicon Research family and look forward to building new projects and capabilities together,” said Parag Sancheti, Rubicon’s CEO.
The 13,000 sqft Impopharma site in Concord, near Toronto, has been previously inspected by the US FDA and Health Canada, and will be the nasal and pulmonary development Center of Excellence in the Rubicon network.
Impopharma Canada has been merged with Rubicon Research Canada Limited, a wholly owned subsidiary of Rubicon Research Private Limited.
To learn more about the pharmaceutical manufacturing environment and what it entails, the Cleanroom Technology Conference is running in Hyderabad, India, in November.
